GSK's Arexvy RSV Vaccine Shows Positive Preliminary Results in Adults Aged 50-59

Phase 3 trial shows GSK's RSV vaccine Arexvy effective for adults aged 50-59, particularly those with underlying medical conditions, augmenting hope to expand its use beyond already approved age group of 60 and older.

GSK's Respiratory syncytial virus (RSV) vaccine, Arexvy, showed positive preliminary results in a Phase 3 trial involving adults aged 50-59, especially those with underlying conditions such as chronic pulmonary disease, cardiovascular disease or diabetes.
The findings from the trial show that Arexvy elicited an immune response in the said age group, matching or surpassing the response observed in adults aged 60 and above.
Tony Wood, GSK’s chief scientific officer, stated the trial reinforces the company's confidence in Arexvy's potential to protect adults at increased risk for RSV, and plans to submit these data for regulatory quickly.
The data from the trial are slated to be submitted to the Food and Drug Administration (FDA) and other regulators to support potential label expansions of Arexvy, with the expansion being expected in 2024.
The results underline the potential for extending the use of the RSV vaccine, building on its existing approval for adults aged 60 and above in regions including the United States, Europe, and Japan.